

Patient	1	2	3	4	5	6	7
Gender	Male	Male	Female	Female	Female	Male	Male
Age at BCG vaccination, day	3	1	1	1	1	1	1
Age at presentation, day (month)	177 (5.8)	821 (26.0)	562 (17.9)	530 (17.3)	704 (23.0)	381 (8.6)	216 (7.0)
Duration of symptoms at presentation, day	2	30	5	5	4	120	3
BCG inoculation site	Left arm	Left arm	Left buttock	Left buttock	Left buttock	Left buttock	Left buttock
BCG infection site	Left humerus	Left humerus	Right arm	Left tibia	Left ankle	Right foot	Right knee
BCG strain given	Indian strain II	Indian strain II	Japan strain	Japan strain	Japan strain	Japan strain	Unknown
TB contact	No	No	No	No	No	No	No
Medical conditions	Nil	Transient tachypnoea of newborn	Nil	Small atrial septal defect	Nil	Nil	Dietary-related iron deficiency anaemia
Pain at infection site	+	+	+	+	+	+	+
Swelling	-	+	+	-	+	+	+
Redness and warmth	-	+	+	-	-	-	-
Fever	-	-	+	-	-	-	-
Lymphadenopathy	-	-	-	-	-	-	-
Hepatosplenomegaly	-	-	-	-	-	-	-
Haemoglobin, g/dL	11.50	11.00	10.99	11.90	11.40	11.30	12.81
Total white cell count, x10 ⁹ /L	19.75	16.74	10.15	16.91	11.49	9.83	12.81
Monocytes, x10 ⁹ /L	1.78	0.84	0.91	1.86	1.26	0.49	1.14
Platelets, x10 ⁹ /L	651	509	353	606	410	354	584
C-reactive protein, mg/L	3.4	1.5	12.6	17.0	10.9	0.40	31.6
CD4, g/L	Nil	25	36.7	37.9	43.6	41.3	35.0

Patient	1	2	3	4	5	6	7
CD8, g/L	Nil	27.4	22.9	16.1	24.4	15.0	18.0
IgM, g/L	0.45	0.84	0.32	1.10	1.61	0.43	0.60
IgE, g/L	4.10	96.60	46.60	78.00	2.50	191.00	2.40
Immune workup	Normal	Normal	Normal	Normal	Normal	Normal	Normal
AFB stain	Negative	Negative	Negative	Negative	Negative	Negative	Negative
Mycobacterium PCR	Positive	Positive	Positive	Positive	Positive	Positive	Positive
Mycobacterium culture	M. bovis	M. bovis	M. bovis	M. bovis	M. bovis	M. bovis	M. bovis
Histology	AFB, necrotising granulomatous inflammation	Necrotising granulomas	Necrotising granulomatous inflammation	Necrotising granulomas	Necrotising granulomas	AFB, necrotising granulomatous inflammation	AFB, granulomatous inflammation
Type of infection	Bone	Bone	Soft tissue	Bone	Bone	Bone	Soft tissue
No. of surgeries	1	1	4	1	1	2	5
Mycobacterial drug treatment	RHEL 2 months, then RH 7 months	RHEL 4 months, RE 8 months	RHEL 12 months (recurrence after 1 month of treatment)	RHEZ 2 months, RE 7 months	RHEZL 3 months, then RH 7 months	RHEZ 2 months, RH 5 months (recurrence after 7 months of treatment) RHEL 2 months, RHE 5 months	RHEL 3 months REL 6 months (recurrence after 1 month of treatment)
Drug complications	Nil	Nil	Nil	Nil	Nil	Z-induced transaminitis	Isoniazid resistance
Re-infections	No	No	Yes	No	No	Yes	Yes
Time to recurrence, day	Nil	Nil	30	Nil	Nil	236	27
Follow-up complications	No	No	No	No	No	No	No

R: Rifampicin; E: Ethambutol; H: Isoniazid; L: Levofloxacin; Z: Pyrazinamide
+: present; -: absent; AFB: acid-fast bacilli; BCG: Bacillus Calmette–Guerin; CD4: cluster of differentiation 4; CD8: cluster of differentiation 8; IgM: immunoglobulin M; IgE: immunoglobulin E; MBI: *Mycobacterium bovis* infection; MSMD: Mendelian susceptibility to mycobacterial diseases; PCR: polymerase chain reaction; TB: tuberculosis
Immunological tests for immunodeficiency workup included CD4 and CD8 levels; antibody testing for IgM and IgE levels; nitroblue tetrazolium levels; Mendelian susceptibility to mycobacterial diseases workup and immunological workup, which involved interferon and gene sequence testing.